Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia
- PMID: 15380346
- DOI: 10.1016/j.leukres.2004.03.020
Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia
Abstract
Bone marrow cells of patients with myelodysplastic syndromes (MDS) frequently undergo apoptosis, though the apoptotic cell ratio decreases when overt leukemia (OL) develops. Thus, we compared the expression of the inhibitor of apoptosis protein (IAP) gene family proteins in bone marrow samples from control, MDS, OL transformed from MDS (MDS --> OL), and de novo acute myelogenous leukemia (AML) subjects by the quantitative real-time RT-PCR method and an immunohistochemical approach. Overexpression of mRNA for survivin, cIAP1, NAIP and XIAP was significant in MDS bone marrow cells compared with control samples. However, the expression of mRNA for survivin, cIAP1 and cIAP2 exhibited a remarkable decrease after the development of OL (MDS --> OL). By immunohistochemistry, survivin was found to localize to the nucleus of myeloid cells in the majority of MDS cases. Next, the chronological changes in the expression of IAPs were determined in cases of MDS with evolution of OL. Although the expression of cIAP1 and cIAP2 revealed a sudden or gradual decrease as OL developed, survivin in many cases and XIAP in the majority of cases exhibited a peak of expression before a decline, indicating that these IAPs could be associated with the early events in the development of OL.
Similar articles
-
Expression dynamics of drug resistance genes, multidrug resistance 1 (MDR1) and lung resistance protein (LRP) during the evolution of overt leukemia in myelodysplastic syndromes.Exp Mol Pathol. 2006 Dec;81(3):249-54. doi: 10.1016/j.yexmp.2006.01.004. Epub 2006 Mar 29. Exp Mol Pathol. 2006. PMID: 16566920
-
Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes.Ann Hematol. 2007 Mar;86(3):185-9. doi: 10.1007/s00277-006-0215-0. Epub 2006 Nov 24. Ann Hematol. 2007. PMID: 17124585
-
Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.Acta Haematol. 2000;102(3):115-23. doi: 10.1159/000040984. Acta Haematol. 2000. PMID: 10692673
-
[The role of the inhibitor of apoptosis protein (IAP) family in hematological malignancies].Postepy Hig Med Dosw (Online). 2008 Feb 14;62:55-63. Postepy Hig Med Dosw (Online). 2008. PMID: 18283236 Review. Polish.
-
Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies.Curr Mol Med. 2011 Nov;11(8):633-49. doi: 10.2174/156652411797536723. Curr Mol Med. 2011. PMID: 21902653 Review.
Cited by
-
Cancer and aging: symposium of the 27th annual meeting of the Japanese society for biomedical gerontology, Tokyo.Cancer Immunol Immunother. 2005 Jul;54(7):623-34. doi: 10.1007/s00262-004-0622-9. Epub 2004 Dec 1. Cancer Immunol Immunother. 2005. PMID: 15578182 Free PMC article.
-
Bone marrow cell cycle markers in inherited bone marrow failure syndromes.Leuk Res. 2008 Dec;32(12):1793-9. doi: 10.1016/j.leukres.2008.05.020. Epub 2008 Jul 7. Leuk Res. 2008. PMID: 18606449 Free PMC article.
-
Apoptosis-Related Gene Expression Profiling in Hematopoietic Cell Fractions of MDS Patients.PLoS One. 2016 Nov 30;11(11):e0165582. doi: 10.1371/journal.pone.0165582. eCollection 2016. PLoS One. 2016. PMID: 27902785 Free PMC article.
-
Repeated recruitment of LTR retrotransposons as promoters by the anti-apoptotic locus NAIP during mammalian evolution.PLoS Genet. 2007 Jan 12;3(1):e10. doi: 10.1371/journal.pgen.0030010. Epub 2006 Dec 6. PLoS Genet. 2007. PMID: 17222062 Free PMC article.
-
Anti-leukemic response of a NSAID, tolfenamic acid.Target Oncol. 2014 Jun;9(2):135-44. doi: 10.1007/s11523-013-0274-9. Epub 2013 Apr 23. Target Oncol. 2014. PMID: 23609055
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
